Accuracy of Wang-Koch axial length adjustment formulas in calculating postoperative refractive power in cataract patients with high myopia / 国际眼科杂志(Guoji Yanke Zazhi)

AIM: To compare the accuracy between Wang-Koch axial length adjustment formulas(SRK/TWK, Holladay ⅠWK)and SRK/T, Haigis, Holladay Ⅰ, Hoffer Q in calculating intraocular lens power of cataract patients with high myopia.METHODS: A total of 42 cataract patients with high myopia(57 eyes)were collected. All eyes underwent phacoemulsification combined with intraocular lens implantation surgery in our Hospital from September 2019 to March 2022. They were divided into two groups according to the axial length(AL): group A(27mm≤AL<30mm, 31 eyes)and group B(AL≥30mm, 26 eyes). Patients were followed up at 3mo. The actual postoperative diopter was recorded, and then the refractive mean numerical error(MNE)and mean absolute error(MAE)were calculated.RESULTS: MAE of each formulas was statistically different after surgery(P<0.01), among which the MAE of Holladay ⅠWK and SRK/TWK [0.31(0.08, 0.57), 0.34(0.17, 0.63)D] was lower than other formulas. However, there were no statistical difference between SRK/TWK, Holladay ⅠWK and SRK/T, Haigis formulas [0.61(0.27, 1.02), 0.63(0.22, 1.01)D](P>0.05). MAE were statistically different among the formulas in group A(27mm≤AL<30mm; P<0.01). The MAE of Holladay ⅠWK and SRK/TWK was lower than other formulas [0.18(0.05, 0.51), 0.28(0.16, 0.52)D], but there were no statistical difference with SRK/T and Haigis formulas [0.45(0.18, 0.65), 0.50(0.14, 0.75)D](P>0.05). In group B(AL≥30mm), the MAE of each formulas was statistically different after surgery(P<0.01), among which MAE of Holladay IWK and SRK/TWK was the lowest, followed by SRK/T and Haigis, whereas, Holladay I and Hoffer Q ranked the highest. Furthermore, there were statistical differences between MAE of SRK/TWK, Holladay ⅠWK [0.44(0.23, 0.67), 0.41(0.22, 0.66)D] and SRK/T, Haigis formulas [0.78(0.55, 1.07), 0.75(0.45, 1.25)D](all P<0.05).CONCLUSION: For cataract patients with AL ≥30mm, the Wang-Koch axial length adjustment formulas were relatively accurate in calculating diopter of intraocular lens, and had clinical application value to some extent.

Application of a new strategy of initial combination therapy with intravitreal dexamethasone intravitreal implant and ranibizumab in macular edema secondary to retinal vein occlusion / 中华眼底病杂志

Objective:To observe the short-term efficacy and safety of a new strategy of dexamethasone intravitreal implant (DEX) combined with ranibizumab in the treatment of retinal vein occlusion (RVO) secondary to macular edema (ME) (RVO-ME).Methods:A prospective clinical interventional study. From May 2020 to September 2021, 78 RVO-ME patients with 78 eyes diagnosed in the eye examination of Department of Ophthalmology of The First Affiliated Hospital of Anhui University of Science&Technology were included in the study. Among them, there were 35 males and 43 females, all with monocular disease. Branch retinal vein occlusion (BRVO) was found in 40 patients with 40 eyes; central retinal vein occlusion (CRVO) was found in 38 patients with 38 eyes. According to the treatment strategies, patients were randomly divided into DEX and ranibizumab combination therapy group (initial combination therapy group), DEX monotherapy group and ranibizumab monotherapy group, with 29 eyes, 26 eyes and 23 eyes respectively. Different types of RVO were divided into different treatment groups of BRVO and CRVO. Best corrected visual acuity (BCVA) and frequency domain optical coherence tomography were performed. The BCVA examination was carried out using the international standard visual acuity chart, which was converted into the logarithmic minimum angle of resolution (logMAR) visual acuity during statistics. There were no significant differences in logMAR BCVA ( χ2 =2.376) and central retinal thickness (CRT) ( F=0.052) among the three groups ( P>0.05). After treatment, the patients were followed up every month for 6 months. The changes of BCVA, CRT and the incidence of adverse reactions were observed during follow-up. One-way ANOVA and Kruskal-Wallis H test were used to compare the differences. Results:During the follow-up period, compared with the baseline, the BCVA of the eyes in the initial combination treatment group, DEX treatment group and ranibizumab treatment group were significantly improved ( Z=110.970, 90.359, 207.303), and CRT was significantly decreased ( F=107.172, 88.418, 61.040), the difference was statistically significant ( P<0.01). At 1, 2, 3, 4, 5, and 6 months after treatment, there were significant differences in the mean changes in BCVA between the initial combined treatment group, DEX treatment group, and ranibizumab treatment group ( χ2=34.522, 29.570, 14.199, 7.000, 6.434, 6.880; P<0.05); 1, 2, 3, and 6 months after treatment, the differences were statistically significant ( F=4.313, 7.520, 3.699, 3.152; P<0.05). The time required to improve BCVA by 0.1 logMAR units in the initial combination treatment group, DEX treatment group, and ranibizumab treatment group was 5.73 (3.21, 8.48), 9.97 (6.29, 18.78), and 20.00 (9.41, 37.89) d, respectively; The time required for CRT to drop to 300 μm was 24.31 (21.32, 26.15), 29.42 (25.65, 31.37), and 29.17 (25.28, 36.94) d, respectively. The BCVA improvement of 0.1 logMAR unit and the time required for CRT to decrease to 300 μm in the eyes of initial combined treatment group were shorter than those in the eyes of DEX treatment group and the ranibizumab treatment group, and the differences were statistically significant ( Z=-3.533, -4.445, -3.670, -4.030; P<0.01). Different BRVO treatment groups: 1, 2, 3, 5, and 6 months after treatment, the mean BCVA changes were significantly different ( χ 2=24.989, 21.652, 11.627, 7.054, 9.698; P<0.05); CRVO was different treatment group: 1 and 2 months after treatment, there were significant differences in mean BCVA changes ( χ 2=11.137, 9.746; P<0.05). Two months after treatment, there were significant differences in CRT changes between BRVO and CRVO groups with different treatment regimens ( F=3.960, 3.722; P<0.01). The time required to improve BCVA by 0.1 logMAR unit in the eyes of BRVO and CRVO combined treatment group was shorter than that in the eyes of BRVO, CRVO DEX treatment group and the BRVO, CRVO ranibizumab treatment group, and the differences were statistically significant (BRVO: Z=-2.687, -3.877; P<0.05; CRVO: Z=-2.437, -3.575; P<0.05). The time required for CRT to drop to 300 μm in the CRVO combined treatment group was significantly shorter than that in the CRVO DEX treatment group and the CRVO ranibizumab treatment group, and the difference was statistically significant ( F=6.910, P<0.010); there was no statistically significant difference between the different BRVO treatment groups ( F=1.786, P>0.05). The number of re-treated eyes in the initial combined treatment group and DEX treatment group was less than that in the ranibizumab treatment group, and the difference was statistically significant ( χ 2=18.330, 7.224; P<0.05). The retreatment interval of the eyes in the initial combined treatment group was significantly longer than that in the DEX treatment group and the ranibizumab treatment group, and the difference was statistically significant ( P <0.01). There was no significant difference in the incidence of intraocular hypertension among the initial combined treatment group, DEX treatment group and ranibizumab treatment group ( χ2=0.058, P>0.05). Conclusions:The new strategy of initial combination therapy with DEX and ranibizumab in the treatment of RVO-ME has a better short-term effect. Compared with the monotherapy group, the retreatment interval is shorter, the visual and anatomical benefits are faster, the efficacy lasts longer, and the safety is better.

Application of a new strategy of initial combination therapy with intravitreal dexamethasone intravitreal implant and ranibizumab in macular edema secondary to retinal vein occlusion / 中华眼底病杂志

Objective:To observe the short-term efficacy and safety of a new strategy of dexamethasone intravitreal implant (DEX) combined with ranibizumab in the treatment of retinal vein occlusion (RVO) secondary to macular edema (ME) (RVO-ME).Methods:A prospective clinical interventional study. From May 2020 to September 2021, 78 RVO-ME patients with 78 eyes diagnosed in the eye examination of Department of Ophthalmology of The First Affiliated Hospital of Anhui University of Science&Technology were included in the study. Among them, there were 35 males and 43 females, all with monocular disease. Branch retinal vein occlusion (BRVO) was found in 40 patients with 40 eyes; central retinal vein occlusion (CRVO) was found in 38 patients with 38 eyes. According to the treatment strategies, patients were randomly divided into DEX and ranibizumab combination therapy group (initial combination therapy group), DEX monotherapy group and ranibizumab monotherapy group, with 29 eyes, 26 eyes and 23 eyes respectively. Different types of RVO were divided into different treatment groups of BRVO and CRVO. Best corrected visual acuity (BCVA) and frequency domain optical coherence tomography were performed. The BCVA examination was carried out using the international standard visual acuity chart, which was converted into the logarithmic minimum angle of resolution (logMAR) visual acuity during statistics. There were no significant differences in logMAR BCVA ( χ2 =2.376) and central retinal thickness (CRT) ( F=0.052) among the three groups ( P>0.05). After treatment, the patients were followed up every month for 6 months. The changes of BCVA, CRT and the incidence of adverse reactions were observed during follow-up. One-way ANOVA and Kruskal-Wallis H test were used to compare the differences. Results:During the follow-up period, compared with the baseline, the BCVA of the eyes in the initial combination treatment group, DEX treatment group and ranibizumab treatment group were significantly improved ( Z=110.970, 90.359, 207.303), and CRT was significantly decreased ( F=107.172, 88.418, 61.040), the difference was statistically significant ( P<0.01). At 1, 2, 3, 4, 5, and 6 months after treatment, there were significant differences in the mean changes in BCVA between the initial combined treatment group, DEX treatment group, and ranibizumab treatment group ( χ2=34.522, 29.570, 14.199, 7.000, 6.434, 6.880; P<0.05); 1, 2, 3, and 6 months after treatment, the differences were statistically significant ( F=4.313, 7.520, 3.699, 3.152; P<0.05). The time required to improve BCVA by 0.1 logMAR units in the initial combination treatment group, DEX treatment group, and ranibizumab treatment group was 5.73 (3.21, 8.48), 9.97 (6.29, 18.78), and 20.00 (9.41, 37.89) d, respectively; The time required for CRT to drop to 300 μm was 24.31 (21.32, 26.15), 29.42 (25.65, 31.37), and 29.17 (25.28, 36.94) d, respectively. The BCVA improvement of 0.1 logMAR unit and the time required for CRT to decrease to 300 μm in the eyes of initial combined treatment group were shorter than those in the eyes of DEX treatment group and the ranibizumab treatment group, and the differences were statistically significant ( Z=-3.533, -4.445, -3.670, -4.030; P<0.01). Different BRVO treatment groups: 1, 2, 3, 5, and 6 months after treatment, the mean BCVA changes were significantly different ( χ 2=24.989, 21.652, 11.627, 7.054, 9.698; P<0.05); CRVO was different treatment group: 1 and 2 months after treatment, there were significant differences in mean BCVA changes ( χ 2=11.137, 9.746; P<0.05). Two months after treatment, there were significant differences in CRT changes between BRVO and CRVO groups with different treatment regimens ( F=3.960, 3.722; P<0.01). The time required to improve BCVA by 0.1 logMAR unit in the eyes of BRVO and CRVO combined treatment group was shorter than that in the eyes of BRVO, CRVO DEX treatment group and the BRVO, CRVO ranibizumab treatment group, and the differences were statistically significant (BRVO: Z=-2.687, -3.877; P<0.05; CRVO: Z=-2.437, -3.575; P<0.05). The time required for CRT to drop to 300 μm in the CRVO combined treatment group was significantly shorter than that in the CRVO DEX treatment group and the CRVO ranibizumab treatment group, and the difference was statistically significant ( F=6.910, P<0.010); there was no statistically significant difference between the different BRVO treatment groups ( F=1.786, P>0.05). The number of re-treated eyes in the initial combined treatment group and DEX treatment group was less than that in the ranibizumab treatment group, and the difference was statistically significant ( χ 2=18.330, 7.224; P<0.05). The retreatment interval of the eyes in the initial combined treatment group was significantly longer than that in the DEX treatment group and the ranibizumab treatment group, and the difference was statistically significant ( P <0.01). There was no significant difference in the incidence of intraocular hypertension among the initial combined treatment group, DEX treatment group and ranibizumab treatment group ( χ2=0.058, P>0.05). Conclusions:The new strategy of initial combination therapy with DEX and ranibizumab in the treatment of RVO-ME has a better short-term effect. Compared with the monotherapy group, the retreatment interval is shorter, the visual and anatomical benefits are faster, the efficacy lasts longer, and the safety is better.

Correlation between disorganization of retinal inner layers and visual prognosis after vitrectomy in proliferative diabetic retinopathy patients / 中华眼底病杂志

Objective:To analyze the correlation between disorganization of retinal inner layers (DRIL) and visual prognosis after pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy (PDR).Methods:A retrospective observational systematic cases study. From January 2019 to January 2020, 52 patients (58 eyes) with PDR who were treated with PPV in the department of ophthalmology of The First Affiliated Hospital of Anhui University of Science & Technology were included in the study. There were 24 males (29 eyes) and 28 females (29 eyes), aged from 45 to 80 years old, with the mean age of 62.95 ±9.38 years. All patients were examined BCVA by using international standard visual acuity chart, and the results were converted into logMAR visual acuity in stastistics. The mean preoperative logMAR BCVA was 2.51±0.69. All patients underwent 23G standard PPV by the same physician. Spectral domain-OCT (SD-OCT) was performed to measure DRIL length within 1 mm of macular area diameter, ellipsoid zone (EZ) fracture length and foveal retinal thickness (CMT) one month after operation. According to the length of DRIL, the patients were divided into three groups: non-DRIL group, DRIL≤500 μm group and DRIL> 500 μm group. The differences of BCVA and the SD-OCT parameters were compared among the three groups after PPV. The postoperative BCVA of the three groups were compared by Kruskal-Wallis H test, and the pairwise comparison between the three groups were performed by Bonferroni correction method. Wilcoxon rank sum test was used to compare BCVA in each group at 1 and 6 months after operation. Spearman rank correlation analysis was used to analyze the correlation between BCVA and measurement parameters of SD-OCT at 1, 3 and 6 months after operation. Multivariate stepwise regression analysis was used to analyze the related factors of visual prognosis after operation. Results:At 1 month after operation, the differences in DRIL length ( χ2=52.194, P=0.000) and EZ fracture length ( F=9.558, P=0.000) among the three groups were statistically significant, but there was no significant difference in CMT ( F=0.817, P =0.447). At 1 and 3 months after operation, there were no significant differences in BCVA between the non-DRIL group and the DRIL≤500 μm group ( Z=-1.846, -2.224; P=0.195, 0.078), however, the BCVA of patients in non-DRIL group was better than that of patients in DRIL≤500μm group at 6 months after operation, and the difference was statistically significant ( Z=-2.508, P=0.036). The BCVA of patients in non-DRIL group at 1, 3 and 6 months after operation was better than that of patients in DRIL> 500 μm group, and there were significant differences ( Z=-5.992, -6.275, -6.497; P<0.01). The BCVA of the DRIL≤500 μm group was better than the DRIL> 500 μm group, and the differences were statistically significant ( Z=-4.260, -4.161, -4.099; P<0.01). The comparison of intra-group among the three groups showed that the BCVA of the non-DRIL group and the DRIL ≤ 500 μm group at 6 months after operation were higher than that at 1 month after operation, and the differences were statistically significant ( Z=-3.525, -3.420; P<0.01). There was no significant difference in BCVA between 6 months after operation and 1 month after operation in DRIL> 500 μm group ( Z=-0.422, P=0.673). The results of Spearman rank correlation analysis showed that a strong correlation was between the length of DRIL and logMAR BCVA at 1, 3 and 6 months after operation ( r s=0.896, 0.918, 0.940; P<0.01). The rupture length of EZ was moderately correlated with logMAR BCVA at 1, 3 and 6 months after operation ( r s=0.488, 0.502, 0.521; P<0.05). There was no significant correlation between CMT and logMAR BCVA at 1, 3 and 6 months after operation ( r s=0.243, 0.220, 0.193; P>0.05). Multivariate stepwise regression analysis showed that DRIL length was the main predictor of postoperative visual acuity recovery ( R2=0.703, P=0.000). Conclusion:The length of DRIL and the rupture length of EZ are correlated with the visual prognosis of patients with PDR after PPV, and there is a strong correlation between DRIL and postoperative visual acuity.

Clinical analysis on T2DM and xerophthalmia after cataract surgery / 眼科新进展

Objective To explore the relationship of T2DM with xerophthalmia after cataract surgery.Methods Retrospective analysis was made on the clinical data of 137 cataract patients (176 eyes) from April,2016 to October,2016.The DM patients were chosen as the DM group (58 cases,71 eyes),and single cataract ones were chosen as the control group (79 cases,105 eyes).The clinical data and xerophthalmia index were compared between two groups.Results The age and sex constituent ratio of DM group and control group had no significant difference (all P ＞ 0.05).The postoperative MQ score,BUT,FL,SⅠt of DM group at 1 week,1 month and 3 months were significantly worse than those at preoperative 2 days (all P ＜ 0.01),but the indexes relieved with time prolong.The postoperative MQ score,FL,SⅠt of control group at 1 week,1 month were significantly worse than those at preoperative 2 days (P ＜ 0.01),the postoperative BUT and preoperative BUT had no significant difference (P ＞ 0.05),all of the postoperative index and preoperative index had no significant difference(all P ＞ 0.05).The postoperative MQ score,BUT,FL,SⅠt of DM group at 1 week,1 month and 3 months were significantly worse than those of the control group (all P ＜ 0.01).Conclusion The xerophthalmia after cataract surgery of T2DM patients are more seriously than normal cataract patients.

Comparative study on HPLC specific chromatogram of Oldenlandia corymbosa Linn. and Oldenlan diadiffusa(Willd.) Roxb / 中国药学杂志

OBJECTIVE: To establish the HPLC specific chromatogram of Oldenlandia corymbosa Linn. and Oldenlan diadiffusa (Willd.) Roxb. in different regions so as to distinguish these two traditional Chinese medicinal materials. METHODS: HPLC was performed on an Agilent Eclipse XDB-C18(4.6 mm×250 mm,5 μm) column with mobile phase consisting of methanol-water at a flow rate of 1 mL·min-1, column temperature at 30℃ and detection wavelength at 254 nm. Similarity evaluation system for chromatographic fingerprint of TCM was used to conduct similarity evaluation and Matlab7.0 software was used for principal component and cluster analysis. RESULTS: Oldenlandia corymbosa Linn. and Oldenlan diadiffusa (Willd.) Roxb. had eight common peaks, namely, a-h; the characteristic peaks of O. corymbosa were 7 to 12, while the characteristic peaks of O. diffusa were 1 to 6. The similarity values of O. corymbosa and O. diffusa collected from different sources were 0.733-0.984 and 0.873-0.951, respectively. According to the principal components analysis and cluster analysis, the tested samples were classified into three categories: O. corymbosa collected from wild, O. diffusa collected from wild and purchased O. diffusa. CONCLUSION: The established method is reliable and rapid to distinguish the two kinds of easily confused traditional Chinese medicinal materials and also can offer reference for their quality control and clinical use.

Analysis of different dosage forms of Xiasangju granules on fingerprints and models using high performance liquid chromatography / 中国中药杂志

To establish the fingerprints of Xiasangju granules (with sugar and non-sugar forms) by HPLC, and provide reference for their identification and effective quality control. High performance liquid chromatography (HPLC) method was used to collect the fingerprints of 20 batches of non-sugar Xiasangju granules and 34 batches of sugar type Xiasangju granules. Their main different components were classified and screened by mode identification methods (principal component analysis, PCA, and orthogonal partial least squares discriminate analysis, OPLS-DA). The principal components were identified by comparing with reference standards. The fingerprints of Xiasangju granules (sugar type and non-sugar type) were established. PCA could not fully classify the two types of granules, while OPLS-DA could obviously classify these two different types of Xiasangju granules. Six components showed greatest difference between two types of granules, including salviaflaside, luteoloside and linarin. The developed mode identification method is helpful to control the overall quality of Xiasangju granules, and it provides an effective approach to quality evaluation.

Research on biological detoxification of Chinese medicine containing aristolochic acid A by ten microorganisms / 中国中药杂志

This paper was aim to screen microorganisms with attenualed efficiency for Chinese medicine containing aristolochic acid A by liquid-state fermentation. Twelve Chinese medicine were detected by UPLC and aristolochic acid A was only founded in four species of Aristolochia, those were Caulis Aristolochiae Manshuriensis, Aristolochiae Radix, Aistolochia Contorta Bunge and Herba Aristolochiae Mollissima,but not in the others. With the four Chinese medicine containing aristolochic acid A as raw material, ten microorganisms were tested, and the content of aristolochic acid A was detected by UPLC. The results showed that one microorganism can decrease content of aristolochic acid A in all those four Chinese medicine.

Photocoagulation with 532 semiconductor laser in the treatment of diabetic retinopathy / 中国基层医药

Objective To observe the photocoagulation treatment effect of using 532 semiconductor laser in the treatment of diabetic retinopathy .Methods A total of 50 cases(95 eyes) of nonproliferative and proliferative dia betic retinopathy received local retinal photocoagulation ,grid photocoagulation or panretinal photocoagulation treatment carried out by 532 semiconductor laser .We observed visual acuity ,slit lamp biomicroscopy ,intraocular pressure ,oph-thalmoscopy,fundus fluorescence angiography (FFA) and optical coherence tomography (OCT).These patients were followed up for 6 months after laser treatment .Results Among the 95 eyes,visual acuity was improved in 36 eyes (37.9%),unchanged in 52 eyes(54.7%) and decreased in 7 eyes(7.4%).Among the 26 eyes with clinical signifi-cant macular edema ( CSME ) , macular edema was resolved completely or partly resolved after photocoagulation . Conclusion Photocoagulation with 532 semiconductor laser in the treatment of diabetic retinopathy was safe and ef-fective.

Study on testing methods of the elastic nature for equivalent material of human skin / 生物医学工程学杂志

To the specificity of equivalent material of human skin mechanical properties, the static-load pressing method for testing the elastic nature of the equivalent material of human skin is proposed, and the designs experimental set for the test is designed. The result show that the method is correct and feasible.